Minapharm acquires ProBioGen for €30 million
This article was originally published in Scrip
Minapharm Pharmaceuticals of Egypt has acquired 95% of the share capital of the privately held German firm ProBioGen for €30.4 million, which includes earn-out payments that are conditional on achieving certain milestones.
You may also be interested in...
Sandoz has named Peter Stenico as permanent country head for its German operations. At the same time, Stada has appointed a trio of executives to key roles in Germany, Hovione has announced a new COO, Hikma and Orion have seen board changes and Sanofi’s biosimilars head in China has left the position for a new role.
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.